JP7538044B2 - 間葉系間質細胞エキソソームおよびそれらの使用 - Google Patents

間葉系間質細胞エキソソームおよびそれらの使用 Download PDF

Info

Publication number
JP7538044B2
JP7538044B2 JP2020560991A JP2020560991A JP7538044B2 JP 7538044 B2 JP7538044 B2 JP 7538044B2 JP 2020560991 A JP2020560991 A JP 2020560991A JP 2020560991 A JP2020560991 A JP 2020560991A JP 7538044 B2 JP7538044 B2 JP 7538044B2
Authority
JP
Japan
Prior art keywords
subject
thymic
exosomes
msc
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523106A5 (https=
JPWO2019217091A5 (https=
JP2021523106A (ja
Inventor
コーレンバナス，ステラ
ミチアリス，エス．，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2021523106A publication Critical patent/JP2021523106A/ja
Publication of JP2021523106A5 publication Critical patent/JP2021523106A5/ja
Publication of JPWO2019217091A5 publication Critical patent/JPWO2019217091A5/ja
Priority to JP2024033810A priority Critical patent/JP2024138218A/ja
Application granted granted Critical
Publication of JP7538044B2 publication Critical patent/JP7538044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020560991A 2018-04-30 2019-04-26 間葉系間質細胞エキソソームおよびそれらの使用 Active JP7538044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024033810A JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664696P 2018-04-30 2018-04-30
US62/664,696 2018-04-30
PCT/US2019/029275 WO2019217091A1 (en) 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024033810A Division JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Publications (4)

Publication Number Publication Date
JP2021523106A JP2021523106A (ja) 2021-09-02
JP2021523106A5 JP2021523106A5 (https=) 2022-05-10
JPWO2019217091A5 JPWO2019217091A5 (https=) 2022-05-10
JP7538044B2 true JP7538044B2 (ja) 2024-08-21

Family

ID=68466806

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560991A Active JP7538044B2 (ja) 2018-04-30 2019-04-26 間葉系間質細胞エキソソームおよびそれらの使用
JP2024033810A Pending JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024033810A Pending JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Country Status (6)

Country Link
US (1) US12521418B2 (https=)
EP (1) EP3810271A4 (https=)
JP (2) JP7538044B2 (https=)
CN (1) CN112334190B (https=)
CA (1) CA3098514A1 (https=)
WO (1) WO2019217091A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN111281889A (zh) * 2020-04-16 2020-06-16 博生众康(厦门)医药生物技术股份有限公司 人脐带间充质干细胞外泌体的用途
US12590310B2 (en) * 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
CN117363568B (zh) * 2023-12-04 2024-04-09 山东大学 一种脂肪间充质干细胞外泌体及其制备方法与应用
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517505A (ja) 2014-05-18 2017-06-29 チルドレンズ メディカル センター コーポレーション エキソソームに関連する方法および組成物
JP2017526723A (ja) 2013-09-16 2017-09-14 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法
WO2017218964A1 (en) 2016-06-17 2017-12-21 United Therapeutics Corporation Extracellular vesicles with enhanced potency

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
BRPI0617085A2 (pt) 2005-09-02 2016-11-08 Agency Science Tech & Res método para obter uma célula-tronco mesenquimal (msc), célula ou linhagem celular, método para derivar uma cultura celular a partir de uma célula-tronco embrionária, método para tratamento de uma doença, uso de uma célula-tronco mesenquimal, linhagem diferenciada, composição farmacêutica, método para condicionar um meio de cultura celular, meio condicionado e uso do mesmo, mpetodo para obterum polipeptídeo, método para obtar uma cultura celular, cultura celular, célula-tronco mesenquimal, linhagem de célula-tronco mesenquimal ou uma célula mesenquimal diferenciada
WO2007124594A1 (en) 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
EP2076116A4 (en) 2006-10-11 2010-04-07 Gen Hospital Corp COMPOSITIONS, METHODS, AND DEVICES FOR TREATING HEPATIC DISEASES
EP1944361A1 (en) 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
CA2711218C (en) 2008-01-04 2019-08-06 Lydac Neuroscience Limited A method of producing a population of differentiated cells
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
EP2456861A4 (en) 2009-07-23 2013-12-04 Agency Science Tech & Res PRENATAL MESENCHYMAL STEM CELLS
SG2014010698A (en) 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states
KR101189655B1 (ko) 2010-06-30 2012-10-11 성균관대학교산학협력단 줄기세포 배양액을 포함하는 폐질환 치료용 조성물
CN101890050B (zh) 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
CA2845280A1 (en) 2010-08-13 2012-02-16 Paul Shiels Therapeutic uses of microvesicles and related micrornas
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CA2829586C (en) 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
EP2721179A4 (en) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
ITTO20111183A1 (it) 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
US9427450B2 (en) 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
SG11201406336YA (en) 2012-04-03 2014-11-27 Reneuron Ltd Stem cell microparticles
KR101399056B1 (ko) 2012-04-16 2014-05-27 연세대학교 산학협력단 줄기세포-유래 미세소포체를 유효성분으로 포함하는 신경질환 예방 또는 치료용 약제학적 조성물
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome
EP2850178A4 (en) 2012-05-18 2015-10-28 Agency Science Tech & Res EXOSOMES OF MESHCHYMIC STROKE CELL OF UMBILICAL CORD
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
AU2013302526B2 (en) 2012-08-15 2018-03-22 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
CN103767985A (zh) 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
ES2927175T3 (es) 2013-02-12 2022-11-03 Reneuron Ltd Método de producción de micropartículas
AU2014251388B2 (en) 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
WO2015018915A1 (de) 2013-08-07 2015-02-12 Pi Ceramic Gmbh Keramische Technologien Und Bauelemente Piezokeramischer werkstoff mit reduziertem bleigehalt
US20180273906A1 (en) * 2014-04-17 2018-09-27 Muhammad Ashraf Microvesicle and stem cell compositions for therapeutic applications
EP3193890A4 (en) * 2014-09-15 2018-03-14 Agency For Science, Technology And Research Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
US10166254B2 (en) 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
US20210205370A1 (en) * 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
CN105769916B (zh) 2016-04-29 2019-07-23 南京大学 间充质干细胞来源外泌体在制备治疗子痫前期药物或者制剂中的应用
KR101973284B1 (ko) 2017-01-16 2019-04-29 사회복지법인 삼성생명공익재단 신생아 ｈｉｅ 치료용 조성물
WO2018183825A1 (en) 2017-03-31 2018-10-04 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs
CA3072562A1 (en) 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
US10876753B2 (en) 2018-02-12 2020-12-29 Watsco Ventures Llc Integrated sensor and service port for HVAC equipment or HVAC system
CA3099042A1 (en) 2018-05-09 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosome -treated monocytes and uses thereof
CA3111661A1 (en) 2018-09-05 2020-03-12 Children's Medical Center Corporation Use of mesenchymal stromal cell exosomes in antenatal therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526723A (ja) 2013-09-16 2017-09-14 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法
JP2017517505A (ja) 2014-05-18 2017-06-29 チルドレンズ メディカル センター コーポレーション エキソソームに関連する方法および組成物
WO2017218964A1 (en) 2016-06-17 2017-12-21 United Therapeutics Corporation Extracellular vesicles with enhanced potency

Also Published As

Publication number Publication date
CA3098514A1 (en) 2019-11-14
CN112334190A (zh) 2021-02-05
CN112334190B (zh) 2024-09-20
EP3810271A1 (en) 2021-04-28
US12521418B2 (en) 2026-01-13
JP2024138218A (ja) 2024-10-08
US20210137989A1 (en) 2021-05-13
JP2021523106A (ja) 2021-09-02
EP3810271A4 (en) 2022-01-26
WO2019217091A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP7538044B2 (ja) 間葉系間質細胞エキソソームおよびそれらの使用
KR101974842B1 (ko) 중간엽 줄기 세포의 용도
EP3027738B1 (en) Mscs in the treatment of inflammatory pulmonary diseases
Tokalov et al. Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats
US20200289558A1 (en) Autologous and allogenic macrophages and monocytes for use in therapeutic methods
US20250170183A1 (en) Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
JP2024103800A (ja) 歯髄由来細胞の製造方法
KR102184722B1 (ko) 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
US20170009208A1 (en) Biophysically Sorted Osteoprogenitors From Culture Expanded Bone Marrow Derived Mesenchymal Stromal Cells (MSCs)
JP2024163978A (ja) 間葉系間質細胞エキソソーム処置単球およびそれらの使用
Abedi et al. Robust conversion of marrow cells to skeletal muscle with formation of marrow-derived muscle cell colonies: a multifactorial process
BR112017014361B1 (pt) Uso de uma população de células-tronco mesenquimais (MSCS) modificadas com fucosiltransferase VI (FTVI) que expressa o ligante de E-L Selectina de célula hematopoiética (HCELL) para tratar diabetes
KR20220152240A (ko) 염증성 장 질환 ii의 치료 방법
WO2021153719A1 (ja) 歯髄由来細胞を含む医薬組成物
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN115361957A (zh) 治疗炎症性肠病的方法i
Class et al. Patent application title: MESENCHYMAL STROMAL CELL EXOSOMES AND USES THEREOF
Li et al. Modulating the phenotype and function of bone marrow-derived macrophages via mandible and femur osteoblasts
Abedi et al. Critical variables in the conversion of marrow cells to skeletal muscle
Park et al. Co-transplantation of human mesenchymal stem cells promotes human CD34+ cells engraftment in a dose-dependent fashion in NOD/SCID mice
KR101503020B1 (ko) 뉴로펩티드 y를 유효성분으로 포함하는 골다공증의 예방 또는 치료용 약학적 조성물
CN118697899A (zh) 一种靶向脂肪细胞治疗骨质疏松症的纳米酶的制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240808

R150 Certificate of patent or registration of utility model

Ref document number: 7538044

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150